ENZEEVU
GrowthBLAINJECTIONINJECTABLE
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ENZEEVU by Novartis is factor-a (vegf-a) and placental growth factor (plgf) are members of the vegf family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. First approved in 2024.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENZEEVU is a fusion protein injectable approved by Novartis in August 2024. The specific therapeutic target and indication remain undisclosed in available data. As a fusion modality product, it represents a novel mechanistic approach to treatment.
Growth
Recent launch positions this as a growth-stage asset with expanding team hiring for commercialization and market development roles.
Mechanism of Action
factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ENZEEVU represents a recent launch into growth phase, creating near-term hiring demand across commercial and medical functions. Early career entry offers exposure to product positioning, market development, and evidence-building for a novel fusion modality.
Brand Manager
Worked on ENZEEVU at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.